Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pegylated irinotecan NKTR 102
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Pegylated Irinotecan NKTR 102 in Treating Patients with Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 225612, NCI-2013-01142, NCT01876446
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-PIR-09, NCI-2012-02730, NCT01457118
Pegylated Irinotecan NKTR 102 in Treating Patients with Refractory Brain Metastasis from Non-small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LUN0067, NCI-2014-02101, NCT02312622
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 12-102-12, NCI-2014-00806, NCT01976143
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-102-13, NCI-2013-01610, NCT01991678
Start Over